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A B S T R A C T
Objective: In this prospective study, we assessed the utility of a novel prognostic score (PS) in guiding the
surgical strategy of patients with sensorimotor area gliomas.
Patients and methods: Form December 2012 to April 2016, we collected data from patients diagnosed with brain
gliomas in the sensorimotor area. All the patients had intraoperatively confirmed contiguity or continuity with
sensorimotor cortical and subcortical structures. Several clinical and radiological factors were analyzed to
generate a PS for each patient (range 1–8). The end-points included the extent of resection (EOR) and neuro-
logical outcome (modified Rankin Score; mRS). We assessed the predictive power of the PS using different
analyses. Crosstabs analyses and Fisher’s exact test (Fet) were used to evaluate the possible predictive para-
meters, and for the classification of positive or negative outcomes for the chosen proxies; the significance
threshold was set at p < 0.05.
Results: Using independent t-tests, we compared the mRS at different time points (pre, post, and at 6 months) for
2 subgroups from the total sample using a cut-off PS value of 4. For the EOR, a PS value of ≥5 was predictive of
successful outcome, a value of 4 indicated an uncertain outcome, and a value of ≤3 predicted a worse outcome.
Conclusions: This PS value can be easily used in clinical settings to help predict the functional outcome and EOR
in sensorimotor area tumors. Integration with information from fMRI, DTI, and TMS, along with MRI spectro-
scopy could further enhance the value of this PS.
1. Introduction
The surgical approach for gliomas in highly functional areas aims to
achieve large surgical resection to improve oncological prognosis and
functional preservation to maintain an optimal postoperative functional
status [1]. This objective of wider resection is easily achievable in
certain locations, but may be difficult at certain other sites, including an
eloquent area or more generally critical area. Furthermore, an onco-
logically desirable resection always should be balanced with the need to
preserve neurological function, in both high and low grade gliomas
(HGGs and LGGs). Data from recent studies suggest that poor post-
operative functional outcome negatively affects the quality of adjuvant
therapies, and finally the global outcome [2–4]. Although clear evi-
dence has been obtained regarding the factors predicting survival (age,
tumor volume, preoperative neurological status, and location in elo-
quent areas) [5–13], information on reliable indices predicting
functional outcome and EOR is scarce. Moreover, an eloquent location
can hinder larger resection and is associated with a greater risk of
postoperative deficits. Nevertheless, the availability of the direct map-
ping technique has helped overcome this limitation, and facilitates safe
and large resection by exploiting interindividual variability and brain
plasticity [14–18]. However, it would be useful to determine the spe-
cific patient characteristics that enhance the risk of new neurological
deficits. In fact, the ultimate goal involves the ability to predict the risk
of a specific neurologic deficit for a given lesion at a particular site in
the brain [19]. In our previous retrospective study [20], we assessed the
gliomas in eloquent areas to determine the clinical and neuror-
adiological parameters that predominantly affect the extent of resection
(EOR) and immediate and late neurological outcome. We observed that
factors related to the biology and morphology of the tumor, along with
the clinical presentation, clearly helped define the operative risks in
terms of the EOR and functional outcome. Based on this evidence, we
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identified factors with the best predictive power to create an in-house
prognostic score (PS). We decided to apply this PS to only sensorimotor
area gliomas, rather than language area gliomas, as these tumors are
associated with less variable cortico-subcortical structures (i.e. primary
motor cortex, premotor cortex, primary sensory areas, and cortico-
spinal tract).
Here, we describe the results of our prospective study on this novel
clinico-radiological PS that can help define the surgical strategy for
patients with sensorimotor area gliomas.
2. Patients and methods
Form December 2012 to April 2016, we analyzed from a
prospectively collected database of patients diagnosed with brain
gliomas of the sensorimotor area. The inclusion criteria were as follows:
the presence of suspected glioma infiltrating or in close vicinity to the
precentral or postcentral gyri and cortico-spinal tract; availability of
preoperative and follow-up clinical and neuroradiological data; and
intraoperative confirmation of eloquence through intraoperative mon-
itoring or cortico-subcortical electrical stimulation. The last criterion
was vital to enhance the reliability of the PS. The positions of the
sensory and motor areas were determined anatomically (axial T1 and
T2) or through functional magnetic resonance imaging and diffusion
tensor imaging (in cases where the precentral and postcentral gyri and
CST were severely compressed or dislocated). When feasible, we follow
a criteria of proposing awake surgery in patients with sensorimotor area
tumors in order to obtain more detailed mapping, particularly in cases
with important subcortical infiltration. However, intraoperative mon-
itoring (IOM) in an asleep patient was chosen when the patient was
unsuitable for awake surgery, and the tumor volume and subcortical
infiltration were limited. Exclusion criteria were as follow: age under
18; patients with relapse/progression of a previously operated tumor.
The preoperative data used to calculate the PS included clinical and
neuroradiological parameters. Clinical parameters were: the presence
of seizures at onset and presence of paresis/dysesthesias. These deficits
were considered regardless they responded or not to steroid adminis-
tration. Neuroradiological parameters were: 1. morphology of the
Fig. 1. MRI index of subcortical infiltration.The red star indicates that the tumors show a prominent cystic component. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
Table 1
Neuroradiological and clinical factors which are considered to calculate the prognostic
score (PS).
+ sharp margins yes [1] no [0]
+ cyst yes [1] no [0]
+ seizures at onset yes [1] no [0]
− MRI index> 2 yes [1] no [0]
− volume>80cm3 yes [1] no [0]
− presumptive higher grade of malignancy yes [1] no [0]
− paresis/dysesthesia yes [1] no [0]
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tumor margins (sharp or diffuse); 2. presence of cysts (large cystic
borders surrounding the tumor); 3. tumor volume (in cm3; tumor’s
volume threshold was fixed at 80 cm3). Volume’s calculation was per-
formed by approximation to the volume of a sphere or ellipsoid on
gadolinium-enhanced MRI or on T2 FLAIR for non-enhancing tumors;
4. degree of subcortical white matter infiltration based on our pre-
viously described MRI index of infiltration (Fig. 1). Briefly, the visual
anatomical limit on MRI to define the infiltration of subcortical con-
nections was the end of the sulcus. The MRI patterns of invasion of the
subcortical white matter were classified into 5 groups: (1) tumors in-
vading and confined to only 1 gyrus; (2) tumors invading 1 gyrus with
extension to white matter and/or adjacent gyrus; (3) tumors infiltrating
up to 3 gyri and extending toward the long range white matter tracts;
(4) tumors primarily located in the white matter below eloquent gyri;
and (5) lobar tumors presumed high tumor grade based on contrast
uptake. All the neuroradiological features were assessed by at least one
neuroimaging expert. Further details regarding the determination of
these prognosticators have been described previously [20].
The end-points included the EOR and the postoperative neurological
status, expressed as the modified Rankin Score (mRS), at 1 and 6
months. The EOR was defined as gross total resection (GTR) in cases
where≥95% of tumor volume was resected, subtotal resection (STR) in
cases where 85–95% of tumor volume was resected, and partial resec-
tion (PR) in cases where<85% of tumor volume was resected.
Once the clinical and neuroradiological parameters were recorded,
a value of 0 or 1 was assigned based on the presence or absence of that
specific factor, as shown in Table 1. These values were then added or
subtracted based on the following formula:
PS = 5 +Margins + Cysts + Seizure - Paresis - MRI index>2 -
Volume>80 cm3 - Contrast enhancement. The resulting values range
between 1 and 8, wherein a higher value is indicative of a better out-
come.
2.1. Intraoperative protocol
Awake cortical and subcortical mapping is performed through a
bipolar fork measuring 6 mm in distance between the electrodes which
delivers a non-deleterious, biphasic square-wave current in 4-s trains at
60 Hz. Stimulation began at 1 mA and increases by 0.50 mA until
generation of contralateral side movement or a paraesthesia occur.
Every positive site is restimulated to confirm reproducibility of stimuli.
For subcortical tumors, we test motor or sensory sites throughout the
subcortical resection, stopping whenever anomalies appear. Motor re-
sponses following cortical and subcortical stimulation are checked via
both direct observation of the patient and electromyography (EMG).
In asleep patients, intraoperative identification of the central sulcus
and the central region was made using a combination of somatosensory
evoked potential phase reversal and direct monopolar anodal high-
frequency electrical stimulation of the cortex.
2.2. Statistical analysis
Statistical analyses and descriptive statistics were performed using
IBM SPSS Statistics 20.0.0 software (SPSS®, IBM®, https://www.ibm.
com/analytics/us/en/technology/spss).
We computed the descriptive statistics based on the demographic
and clinical data of the sample. We used 3 proxies to evaluate the po-
sitive/negative outcome: EOR (total or subtotal); 6-month follow-up
mRS (worsened or equal/improved compared to the preoperative mRS);
and a combination of EOR and mRS (0: subtotal resection and worsened
mRS; 1: total resection or better mRS; or 2: total resection and better
mRS).
We also assessed the predictive power of the PS using various
analyses. Crosstabs and Fisher’s exact test (Fet) analyses were used to
evaluate the possible predictive parameters, as well as the classification
of positive or negative outcomes for the chosen proxies; the significance
Table 2
Clinical, radiological and histological patients’ data (mRS, modified Rankin Score; HGG,
high grade glioma).




seizures at onset paresis/dysesthesia at
onset


















PS 4.36 (1.37) 1–7
mRS pre 0.98 (1.07) 0–4
mRS post 2.00 (1.35) 0–4







28 (63.6%) 5 (11.3%)
surgical results
total resection subtotal resection partial
resection
26 (59%) 17 (38.6%) 1 (2.2%)
Table 3
Crosstabs and Fisher’s exact test for outcomes proxies and prognostic index. EOR = Total
resection if 1; mRS = modified Ranking Score improved or unvaried if 1;
Outcome = Good (EOR = 1 and mRS = 1), Mixed (EOR or mRS = 1) or Bad Outcome
(EOR and mRS = 0); PS = Prognostic Score; Fet = Fisher’s exact test, in parentheses the
number of cells. In the columns PS ranged from 1 to 7, in the rows are shown the values of
the outcomes proxies, so for example in the PS = 2 column there were 2 patients with
Bad Outcome and 0 patients with Mixed or Good Outcome.
EOR/PS 1 2 3 4 5 6 7
0 1 2 8 5 2 0 0
1 0 0 1 7 8 8 2
Fet(7 × 2) = 20.79, p < 0.001
mRS/PS 1 2 3 4 5 6 7
0 0 2 3 2 0 0 0
1 1 0 6 10 10 8 2
Fet(7 × 2) = 12.06, p = 0.017
Outcome/PS 1 2 3 4 5 6 7
0 0 2 3 2 0 0 0
1 1 0 5 3 2 0 0
2 0 0 1 7 8 8 2
Fet(7 × 3) = 25.16, p = 0.001
Table 4
Aggregate percent of the PS and outcome proxies. EOR = Total resection if 1;
mRS =modified Ranking Score improved or unvaried if 1; Outcome = Good (EOR = 1
and mRS = 1), Mixed (EOR or mRS = 1) or Bad Outcome (EOR and mRS = 0);
PS = Prognostic Score.
PS EOR mRS Total Outcome
1–3 8% positive 50% positive 58% success (50% mixed 8% positive)
4 58% positive 83% positive 83% success (25% mixed 58% positive)
5 80% positive 100% positive 100% success (20% mixed 80% positive)
6–7 100% positive 100% success (100% positive)
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threshold was set at p < 0.05.
Using 2-sample independent t-tests, we assessed the mRS at dif-
ferent time points (pre, post, and at 6 months) for 2 subgroups from the
total sample based on a cut-off PS value of 4 (for further details refer to
supplemental material).
3. Results
We enrolled a total of 48 patients with tumors in sensorimotor areas
who were undergoing intraoperative mapping or monitoring. Of these
patients, 4 were excluded as the tumor did not exhibit infiltration of the
cortical nor subcortical sensorimotor regions intraoperatively. Table 2
describes the characteristics of the patients.
The PS was found to be associated with certain proxies, as de-
termined by Fet (Table 3) and descriptive statistics (Table 4). For EOR,
a PS value of ≥5 was predictive of successful outcome, a value of 4
indicated an uncertain outcome, and a value of ≤3 predicted a worse
outcome. If only patients with a mRS on follow-up were considered,
those with a PS of 4 exhibited worse or improved mRS values, those
with a PS≥ 5 exhibited improved mRS values, and those with a PS ≤ 3
exhibited worsened mRS values.
In the PS subgroups (Table 5), only the follow-up duration indicated
a significant difference, including greater mRS values in those with
PS<4 and a mean increase in the scores compared to those before
surgery. In fact, the PS outperformed the single indicators (both EOR
Table 5
Functional differences in subgroups with high or low prognostic index. PS = Prognostic
Score: mRS =modified Rankin Score. Mean (SD), in bold p< 0.05.
Score PS < 4 PS≥ 4 p
N 12 32 –
mRS pre 1.2 (1.2) 0.9 (1.0) 0.305
mRS post 2.7 (1.6) 1.7 (1.2) 0.043
mRS follow up 1.9 (1.3) 0.6 (0.8) <0.001
mRS post-pre −1.4 (1.1) −0.9 (1.2) 0.189
mRS follow up-pre −0.7 (1.2) 0.3 (0.8) 0.019
Table 6
Comparison of binary classification for different indicators. Numbers of correctly classi-
fied patients (%). EOR = Total resection if 1; mRS =modified Ranking Score improved
or unvaried if 1; PS = Prognostic Score; HGG = presumptive higher grade of malignancy.
Cut-off EOR mRS
PS [4 or more] 39 (89%) 35 (80%)
Margins [y] 35 (80%) 24 (55%)
Cystic [y] 24 (55%) 19 (43%)
Volume>80 cm3 [y] 17 (39%) 22 (50%)
HGG [y] 25 (57%) 28 (64%)
Seizure [y] 30 (68%) 29 (66%)
Paresis [y] 19 (43%) 20 (45%)
MRI>2 [y] 36 (82%) 25 (57%)
Fig. 2. Upper pictures present two tumors in similar
location but different volume. Both had round mar-
gins and cystic component in contact with the CST.
Seizures were the only complaint for both patients
(patient B had also a very slight sensory syndrome).
Tumors had characteristics of high grade
gliomas.The PS for these patients was equally 5 al-
though tumor in A was almost double in volume. In
the postoperative period both patient had optimal
evolution and complete recovery to fully functioning
life. Both had complete resection as showed in C and
D. Tumor A was an anaplastic oligodendroglioma
and B was glioblastoma.
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and mRS). In the Table 6 a comparison of binary classification for dif-
ferent indicators with the numbers of correctly classified patients.
4. Discussion
When counseling a patient with a tumor located in highly functional
regions of the brain, it is ideal to use methods that accurately predict
the EOR and functional outcome; in such cases, treatment aims to
achieve a low incidence of postoperative permanent neurological def-
icits, as these would markedly affect the global outcome of patients by
delaying adjuvant therapies and eventually reducing survival [2–4].
Such methods would help surgeons choose the best treatment strategy
for specific patients, particularly when considering challenging opera-
tions, such as awake surgery and direct brain mapping. Surgeons ty-
pically consider several factors before choosing a surgical technique,
such as the neurological status, symptoms at onset, tumor volume,
proximity to eloquent regions, mass effect, and presumed malignancy.
Although these are important factors to consider, only limited in-
formation is available on their role and contribution to the outcome
(Fig. 2).
Tumor location is classically a predominant factor influencing the
EOR and functional outcome. Historically, hemispheric gliomas are
classified as far, near, or within eloquent areas, which are related to
increasing risk of postoperative functional deterioration
[7,12,21,22–24]. However, this categorization method is quite re-
ductive and unreliable due to the wide interindividual functional
variability, and even with the help of modern neuroradiologic
advancements such as functional MRI and diffusion tensor imaging, it is
difficult to predict the EOR and functional outcome [24–27]. Accord-
ingly, intraoperative mapping techniques are becoming more com-
monly used, as they enable point-by-point mapping of the cortex and
subcortical tracts with high reliability and reproducibility, as confirmed
by large outcome studies [24,28,29]. Our PS is supported by systematic
intraoperative confirmation through direct stimulation of the cortical
and subcortical pathways. This point should be emphasized, because as
intraoperative confirmation is not possible, the eloquent location of a
tumor remains putative. Thus, a preoperative PS based only on func-
tional or anatomical neuroimaging data may have very low reliability
due to the interindividual variability and plasticity of the functional
areas.
Tumor volume is another critical factor that influences surgery.
However, in a previous study, we found that, although tumor volume is
a determinant for safe surgery, it cannot be solely considered as a
prognosticator and should instead be combined with other patient-
specific factors (subcortical infiltration pattern, grade of malignancies,
presence of preoperative deficits) to generate better predictions. This
concept is evident in the present study, where apparently similar tu-
mors behave in markedly different manners (Fig. 3). A reason for this
phenomenon may involve the microscopic relationship between the
pathologic tissue and the apparently healthy brain (i.e. tumor’s sharp
rounded margins can displace subcortical long tracts better then tumors
with diffuse margins). Moreover, the growth rate can affect the brain
capacity to reshape and adapt. This point is strictly related to the
biology of the tumor (high or low grade) and influences the eventual
Fig. 3. The figure A shows a voluminous tumor extending
into the whole parietal lobe toward the CST. The tumor has
sharp margins and no contrast enhancement. Patient suffered
from long-lasting seizures and slight left sensory syndrome.
The PS for this patient is 4 meaning a degree of uncertainty
about the functional outcome and EOR. In B a tumor in si-
milar location but showing characteristics of higher grade of
malignancy with ill-defined margins; the volume was lower
than the former. The patient presented with severe paresis. In
this case the PS was 2. C and D report the postoperative MRI
showing complete resection in the first patient and subtotal
resection in the second patient. This patient experienced also
a worsening of functional status which did not recovered.
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appearance of focal deficits at onset. Furthermore, the central role of
white matter infiltration on EOR and functional outcome has only re-
cently been recognized [30,31]. Interestingly, this was not strictly re-
lated to the volume of the tumor [20,30,31].
Based on our results, it appears that PS has good predictive value in
discerning between good and bad outcomes, which may be due to the
fact that we restricted analysis to only glial and sensorimotor area tu-
mors. We aimed to create a PS that was applicable to a well-defined
(both clinically and radiologically) type of patient and tumor. As
mentioned previously, tumors located in the so-called “language” areas
should be considered differently, due to the large networking structure
of those areas and the wide spectrum of clinical presentations. The
presence of a “gray zone”—i.e., a PS of 4—is important as it reflects a
common condition where it is difficult to predict reliable outcomes.
The current PS can be applied in cases where the surgeon believes
the tumor is located in proximity of the sensorimotor area. In fact, given
that the PS value functions well in our series of cases with in-
traoperatively demonstrated sensorimotor area infiltration, it will also
be suitable for tumors located in proximity to the sensorimotor areas.
It has to be emphasized that such a PS can help in formulating the
potential risk in operating on sensory-motor located gliomas but it
cannot indicate which kind of surgical techniques to be used (in-
traoperative monitoring, direct mapping etc.).
One limitation of the present study is that the number of patients is
low and were strictly selected. However, this selection strategy was
vital to obtain a homogeneous cohort of patients and yield more co-
herent results. Another possible bias may be related to the fact that all
patients were initially intended to undergo surgery. Moreover, the
grouping of HHG and LLG cases together may confound the results. In
fact, we aimed to demonstrate the manner in which the growth rate and
biology of tumors influence the interaction between the tumor and
brain through different mechanisms (infiltration, dislocation, and
plasticity), which finally affect the EOR and functional outcome. We
foresee a new analysis in which HGG and LGG are analyzed separately.
5. Conclusions and perspectives
Even though it did not include a large sample, this prospective series
clearly showed that the PS can be easily used in the clinical setting to
help predicting the functional outcome and EOR. However, we believe
that this PS should be integrated with other parameters (including
fMRI, DTI, and transcranial magnetic stimulation) to generate a mul-
tifaceted score. Moreover, novel MRI spectroscopy software can also
yield vital information on new biomarkers that can help define tumor
malignancy and indications of the final outcome [32,33].
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